Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414841 | 0.80 | CYP17A1 (0.49) | CYP17A1CYP2C8 | |
| SCHEMBL1414881 | 0.78 | CYP17A1 (0.45) | CYP17A1CYP2C8SIRT2FLT3TYRO3 | |
| SCHEMBL1414929 | 0.78 | SIRT2 (0.36) | SIRT2 | |
| SCHEMBL4023986 | 0.78 | VNN1 (0.36) | SIRT2ENPP2 | |
| SCHEMBL4029004 | 0.76 | NPC1 (0.37) | ENPP2 | |
| SCHEMBL4030987 | 0.75 | MEN1 (0.51) | SIRT2ENPP2 | |
| SCHEMBL313125 | 0.74 | ACSS2 (0.43) | CYP17A1SIRT2 | |
| SCHEMBL4024355 | 0.74 | SIRT2 (0.41) | SIRT2 | |
| SCHEMBL5678341 | 0.74 | KDM4E (0.46) | SIRT2 | |
| SCHEMBL4031880 | 0.74 | CTNNB1 (0.34) | SIRT2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344777-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | CYP17A1 1/4885CYP2C8 137/4885SIRT2 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.